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Small molecule inhibitors of protein kinase CK2 reduce proliferation and viability of mela-
noma cells in vitro
EM Dodd,1 JH Trembley3, 4, 5 and RL Ahmed2 1 University of MN Medical School, Mpls, 
MN, 2 Dermatology, University of MN, Mpls, MN, 3 Molecular and Cellular Biochemistry 
Lab, Minneapolis VA Health Care System, Mpls, MN, 4 Laboratory Medicine and Pathology, 
University of MN, Mpls, MN and 5 Masonic Cancer Center, Mpls, MN
Metastatic melanoma is an aggressive form of skin cancer, which is notoriously resistant to current 
therapies. Long-term survival remains extremely poor, necessitating the development of novel ther-
apeutic targets. Protein kinase CK2 is a constitutively active serine/threonine kinase that acts as a 
potent regulator of cellular viability and is invariably upregulated in all cancers studied to date. Loss 
of CK2 activity induces apoptosis of cancer cells. Our aim was to test the effect of small molecule 
CK2 inhibitors on cellular viability of melanoma cells. Two melanoma cell lines were obtained, 
one of primary tumor origin (A375) and one of metastatic tumor origin (1205Lu). Both lines were 
treated every 24 hours with 4,5,6,7-tetrabromo-1H-benzotriazole (TBB), a well-established CK2 
inhibitor. Cell viability assays were performed on each cell line 24, 48 and 72 hours following initial 
treatment. Whole cell lysates were processed 24 and 48 hours after initial treatment, and western 
blot analysis was used to detect levels of key cell signaling proteins. Both cell lines demonstrated 
significantly decreased viability post-treatment. 1205Lu cells had a >50% reduction in viability 
as early as 24 hours post-treatment with a higher TBB concentration (100 μM) and demonstrated 
similar loss of viability after 72 hours with a lower concentration (20 μM). A375 cells required the 
higher TBB concentration of 100 μM to achieve a >50% decrease in viability. Western blot analysis 
detected altered expression of key signaling pathway proteins in response to CK2 inhibition. Both 
cell lines had decreased levels of pro-proliferative regulators, including NFkB p65 p-Ser529, AKT 
p-Ser129 and cyclin D1. Furthermore, detection of cleaved caspase-3 and lamin A/C proteins 
indicated activation of apoptosis. These findings suggest that CK2 may be a useful novel target for 
melanoma treatment.    
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The role of KIT in early melanoma development
C Posch1, 2, 3, M Sanlorenzo1, 4, H Moslehi,1 I Vujic1, 3, J Oses-Prieto,1 R Esteve-Puig,1 
G Green,1 L Feeney,1 A Burlingame,1 K Rappersberger3 and S Ortiz-Urda1 1 Dermatology, 
University of California San Francisco, San Francisco, CA, 2 Dermatology, Brigham and 
Women’s Hospital, Boston, MA, 3 Dermatology, Krankenanstalt Rudolfstiftung, Vienna, 
Austria and 4 Dermatology, University of Turin, Torino, Italy
In melanoma, mutations in the KIT oncogene are most frequently found in primary tumors arising 
in acral and mucosal skin. Reports indicate that acral melanoma cells can be detected in the distant 
periphery of the primary tumor (field effect). In this study we investigate the contribution of mutant 
KIT to fuel melanoma cell migration. Murine and human KIT mutant cell lines as well as genetically 
manipulated murine and primary human melanocytes were used to investigate the role of mutant 
KIT in melanoma migration. Immunoblotting, migration assays, kinome and phospho-proteomic 
analyses were used to study signaling events. Mouse xenografts of human skin-reconstructs were 
used to analyze migratory properties of KIT mutant cells in vivo. KIT mutant melanoma cell lines 
depend on KIT signaling for survival and migration in vitro using wound healing as well as human 
skin-reconstruct assays. Stably transduced murine and human primary melanocytes have migratory 
advantages compared to their respective control cells and are sensitive to specific KIT inhibitors. 
KIT mutant cells display molecular changes related to increased migration, such as pronounced 
PI3K/mTOR, MEK/ERK and p38-MAPK signaling. In a xenograft model of human skin-reconstructs, 
KIT mutant melanoma has migratory advantages over BRAF and wild type melanomas. Systemic 
treatment of mice with specific KIT inhibitors reduced migration of KIT mutant melanoma cells in 
vivo. In this study, KIT mutations increase the migration of melanocytes. Data points into the direc-
tion, that mutant KIT might contribute to the clinically observed ‘field effect’ in actral melanoma. 
The model of melanoma skin constructs revealed that KIT inhibitors have the potential to reduce 
melanoma cell migration and viability in vivo, suggestive for a beneficial role of KIT inhibitors in 
the early treatment of KIT mutant melanoma.    
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Neurotrophin receptors and perineural invasion in desmoplastic melanoma
N Frydenlund,2 D Leone,3 B Mitchell,2 S Yang4 and M Mahalingam1 1 Dermatology, Boston 
University School of Medicine, Boston, MA, 2 Graduate Medical Sciences, Boston University 
School of Medicine, Boston, MA, 3 School of Public Health, Boston University School of 
Medicine, Boston, MA and 4 Pathology, Boston University School of Medicine, Boston, MA
In melanoma, perineural Invasion (PNI) is most commonly observed in desmoplastic melanoma 
(DM). While the prognostic relevance of PNI is not well establshed in DM compared to other cuta-
neous malignancies, it is reported to be associated with an increased risk of local recurrence and 
reduced disease-free survival. The biological mechanisms underlying PNI remain unclear although 
multiple lines of evidence suggest that neurotrophins and their receptors play a role. Given this, we 
sought to evaluate the relationship between expression of the high- and low- affinity nerve growth 
factor (NGF) receptors (TrkA and p75NGFR respectively),polymorphisms in the RET proto-oncogene 
(encoding a receptor for glial cell line-derived neurotrophic factor) and PNI in a cohort of DMs. 
Additionally, we investigated their relationship to established histopathologic prognosticators. Of 
the 43 cases of DM studied, PNI was present in 29 (67%) of them. On bivariate analysis; p75NGFR 
was significantly associated with PNI, with expression detected in 23/29 (79%) of PNI positive cases 
compared to 5/14 (36%) of PNI negative cases (p=0.005),  p75NGFR expression was associated 
with increased Breslow’s depth, and greater Clark Level (p= 0.007 and p= 0.01 respectively) and, 
functional RET polymorphism, while expressed in 12/43 (28%) of cases, was not significantly 
associated with PNI or any other histopathologic variable investigated. TrkA expression was not 
observed in any of the 43 cases. PNI was also significantly associated with increased Breslow’s depth 
and greater Clark Level (p=0.01 and p=0.009 respectively). On multivariate analysis, controlling for 
depth, p75NGFR expression remained associated with an increased propensity for PNI (OR=4.68, 
p=0.04). Our findings suggest that of neurotrophin receptors studied, p75NGFR may be relevant in 
mediating PNI and a more locally aggressive phenotype.    
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CD4, IL-17, and COX-2 are associated with inflammation in melasma
A Rodríguez-Arámbula1, 2, JP Castanedo-Cázares1, 2, D Cortés-García1, 3, B Torres-Álvarez1, 2 
and KI Martínez-Rosales1, 2 1 Dermatology, Hospital Central “Dr. Ignacio Morones Prieto”, 
San Luis Potosi, Mexico, 2 Dermatology, Facultad de Medicina, Universidad Autónoma de 
San Luis Potosí, San Luis Potosí, Mexico and 3 Laboratory of Immunology and Cellular and 
Molecular Biology, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis 
Potosí, San Luis Potosí, Mexico
Melasma is a common photoinduced hyperpigmentary disorder whose pathogenesis is not clearly 
elucidated. Dermal inflammation caused by solar exposure might be a critical factor through the 
production of melanogenic cytokines, and growth factors. The inflammatory features and the 
role that inflammation plays in this disorder are unknown. Our aim was to describe the ongoing 
characteristics of inflammation in melasma by measuring the cellular infiltrate, the expression of 
inflammatory mediators, and to explore their relationship with severity of disease, solar elastosis, 
and epidermal melanin. Twenty healthy female patients with malar melasma without specific solar 
exposure or photoprotection measures within the previous 3 weeks were enrolled. Disease sever-
ity was estimated using the MASI index. Histological, histochemical, immunohistochemistry, and 
QRT-PCR were used to evaluate the presence of inflammatory cells and mediators in lesions and 
compare them to adyacent skin. Increased lymphocytic infiltrate mainly composed by CD4+T cells, 
CD68+ macrophages, and mast cells were significantly higher in lesional skin. Also, the relative 
expression of mRNA IL-17 and mRNA COX-2 were significantly increased in affected skin (p<0.05, 
and p<0.001, respectively). MASI score was associated with the number of CD4+ T cells and with 
COX-2 stain expression. Solar elastosis and epidermal melanin were only associated with COX-2 
expression. Remarkably, gene expression of acute inflammatory mediators such as IL-1α, IL-1β, 
R-IL1, IL-6, IL-8, VEGF, and TNFα were not increased. Together, these data indicate that melasma 
is characterized by chronic inflammatory cells and mediators, particularly IL-17 and COX-2 which 
could explain its recurrent nature.    
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An epithelial-mesenchymal transition in melanoma is associated with acquired resistance 
to BRAF inhibition
YE Chen,1 Z Ji,2 M Taylor,2 JC Njauw,2 G Jonsson3 and H Tsao2 1 Dermatology, UCSF, San 
Francisco, CA, 2 Wellman Center for Photomedicine, MGH, Boston, MA and 3 Division of 
Oncology, Lund University, Lund, Sweden
Understanding the mechanism of drug resistance is crucial to the development of effective cancer 
therapies. In melanoma, the oncogenic BRAF(V600E) mutation confers extreme sensitivity to BRAF 
inhibition with vemurafenib (VEM). However, melanoma can acquire resistance through multiple 
mechanisms, including BRAF amplification, BRAF splice variation, and upregulation and activa-
tion of receptor tyrosine kinases. In this study, we characterized the changes in transcriptional 
programming that occur in response to VEM in sensitive melanoma cell lines and the changes that 
occur after acquisition of VEM resistance. Using a non-biased microarray approach, we found that 
VEM significantly changed the expression of only a small percent of genes in melanoma cell lines, 
consistent with its action as a selective BRAF inhibitor. We discovered that in vitro selection for VEM 
resistance generated very different degrees of cellular reprogramming. In one cell line, resistance 
emerged from a BRAF splice product, which was associated with minimal changes in cell state. In 
another cell line, resistance was associated with an epithelial to mesenchymal transition, leading 
to melanoma dedifferentiation and decreased reliance on melanocyte-specific survival pathways. 
Our data characterize a novel drug resistance mechanism in melanoma that offers an additional 
pathway for the development of therapeutic approaches.    
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MT19c resensitizes metastatic melanoma cells to vemurafenib, decreases tumor growth, and 
increases survival in a vemurafenib-resistant metastatic melanoma model
A Han, M Vezeridis, R Singh, L Robinson-Bostom, MA Weinstock and R Moore Department 
of Dermatology, Brown University, Providence, RI
Metastatic melanoma is a challenging disease to manage due to limited effective treatment options 
for patients who lack the BRAF mutation (~50%) or who are inherently resistant to BRAF inhibitors. 
Even in BRAF mutant patients, vemurafenib as a first-line therapy often fails due to rapid emergence 
of drug resistance and dose-limiting systemic toxicities. MT19c, a novel non-hypercalcemic Vitamin 
D derivative, showed anti-proliferative effects at nanomolar concentrations against a panel of che-
moresistant and metastatic human melanoma cell lines, including both BRAF mutant and wild-type 
genotypes. National Cancer Institute (NCI) safety studies also found that MT19c causes no acute or 
systemic toxicity in mice, even up to the highest tested 400mg/kg intraperitoneal (IP) dose. MT19c 
was further studied in a BRAF mutant and vemurafenib-resistant metastatic melanoma cell line, 
A2058. MT19c reduced expression of BRAF, phosphorylated BRAF, and downstream MEK and 
ERK1/2 in A2058 cells via western blot and immunohistochemistry, and significantly resensitized 
A2058 cells to vemurafenib treatment (p<0.001). Furthermore, MT19c inhibited angiogenesis by 
suppressing microcapillary formation in an ex vivo rat aortic assay and in vitro tube formation 
assay. We studied the in vivo effects of MT19c in a nude mouse metastatic melanoma xenograft 
model using A2058 cells, which are vemurafenib and MEK inhibitor-resistant, and are known to 
metastasize to the lungs, lymph nodes, and brains. Mice were treated with either MT19c (N=6, 
10mg/kg, IP, 5X/week) or PBS vehicle control (N=6, IP, 5X/week). MT19c treatment significantly 
reduced mean tumor size compared to controls after 10 days of treatment (p=0.012). MT19c also 
significantly decreased mean tumor weight at time of sacrifice after 15 days of treatment (p=0.0038), 
and significantly increased survival (p=0.03). In conclusion, MT19c is a promising safe and novel 
therapeutic which exhibits both in vitro and in vivo efficacy against metastatic melanoma.    
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Dual inhibition of CRD-BP and BRAF in BRAF-mutant Melanoma – A novel approach to 
overcome resistance to BRAF inhibitors
T Kim2, 1, YG Xu,1 V Setaluri1 and V Spiegelman2, 1 1 Dermatology, University of Wisconsin-
Madison, Madison, WI and 2 Molecular and Environmental Toxicology, University of 
Wisconsin-Madison, Madison, WI
Melanoma is the sixth most common cancer in the United States and malignant stages of mela-
noma result in low survival rate. BRAF is the most frequent mutation in human melanoma with the 
majority being V600E (80%). Vemurafenib is one of the FDA approved drug targeting V600E-mutant 
melanoma by inhibiting enzymatic activity of BRAF. Decreased phosphorylation on BRAF results in 
suppressed signaling to the downstream of MAPK pathways. Treatment with vemurafenib extended 
progression-free survival by 6 months after initial treatment, however resistance to vemurafenib 
develops after months of treatment. Although combination therapies with vemurafenib have been 
studied, secondary resistance may occur because multiple mechanisms can be involved in resistance 
to BRAF inhibitor. Here, we propose an approach, independent on the mechanisms of acquired 
resistance, by targeting a molecule critical for regulation of multiple pro-survival pathways in 
melanoma - CRD-BP. CRD-BP is a messenger RNA binding protein that binds to various targets 
such as βTrCP1, c-myc, Gli1, MDR1 and MITF. Binding of CRD-BP affects mRNA translation, 
localization and stability leading to increased survival, inhibition of apoptosis and development of 
drug resistance as well as induction of tumorigenic properties. We hypothesized that inhibition of 
CRD-BP can potentiate the action of BRAF inhibitors and aids in overcoming resistance to BRAF 
inhibitors. Our study shows that combination of BRAF inhibitor and CRD-BP knockdown inhibits 
tumorigenic properties such as reduced cell growth and cell proliferation as well as induction of 
G1 cell cycle arrest and apoptosis. In addition, inhibition of CRD-BP on vemurafenib-resistant cell 
line effectively attenuates the growth with treatment of vemurafenib. These findings indicate that 
CRD-BP may work as a novel target for BRAF-mutant melanoma.    
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Aspirin induces Nrf2-mediated transcriptional activation of heme oxygenase-1 in protection 
of human melanocytes from H2O2-induced oxidative stress
Z Jian, L Tang, T Gao and C Li Department of Dermatology, Xijing Hospital, Fourth Military 
Medical University, Xi’an, China
A growing body of evidences has suggested that oxidative stress is involved in the etiology and 
pathogenesis of vitiligo. In this study, we investigated the effect of aspirin, which is demonstrated 
to have antioxidant property, on H2O2-induced oxidative injury of human melanocytes. Human 
melanocytes were pretreated with different concentrations of ASA for 2 h, followed by exposure 
to 1.0 mM H2O2 for 24 h. Cell apoptosis and reactive oxygen species levels were evaluated by 
flow cytometry, and cell viability was determined by an CCK-8 assay. The expressions of Nrf2, 
phosphorylated Nrf2, and HO-1 were assayed by Western blot to investigate the possible molec-
ular mechanisms. Concomitant with an increase in viability, pretreatment of 10-90 μmol/L aspirin 
resulted a decrease of apoptotic cells and intracellular reactive oxygen species (ROS) in primary 
human melanocytes. The lactate dehydrogenase (LDH) release rate is also significantly decreased 
after the treatment of aspirin. To explore the underline mechanism, we examined the effect of 
aspirin on nuclear factor E2-related factor 2 (Nrf2)-antioxidant response element (ARE) pathway. 
Aspirin dramatically induced the phosphorylation of Nrf2, activated Nrf2 nuclear translocation 
and induced the expression of heme oxygenase-1 in human melanocytes. Knockdown of Nrf2 
expression or pharmacological inhibition of heme oxygenase-1 abrogated the protective action 
of aspirin on melanocytes against H2O2-induced cytotoxicity and apoptosis. These results suggest 
that aspirin has protective effects on melanocytes against H2O2-induced oxidative stress and Nrf2-
driven transcriptional activation of heme oxygenase-1 may be a critically important determinant 
in the cytoprotective effect of aspirin against H2O2. Therefore, we speculate that aspirin might be 
a promising candidate for prevention or treatment of vitiligo.    
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Depletion of melanoma fn14 by oligonucleotide-mediated exon skipping
KM Beck, S Ramaswami, W Zeng and MS Hayden Dermatology, Columbia University, New 
York, NY
Fibroblast growth factor inducible 14 (Fn14) is the receptor for the TNF family cytokine TNF-like 
weak inducer of apoptosis (TWEAK). TWEAK binding triggers multiple signaling pathways down-
stream of Fn14, including the MAPK and NF-κB pathways. Activation of these pathways can promote 
cell survival, proliferation, and inflammation. Fn14 is poorly expressed in the steady state but is 
readily induced by cellular stresses and tissue injury. When highly expressed, Fn14 can activate 
pro-survival and pro-proliferative signaling pathways in a TWEAK-independent manner. Fn14 is 
highly expressed in melanoma and correlates with poor outcomes. Consequently it is thought 
that the Fn14 pathway could be a therapeutic target in melanoma. Given that Fn14 can signal in 
both a TWEAK-dependent and -independent manner, we have developed a strategy to block both 
signaling mechanisms. We utilized an exon-skipping approach to alter the mRNA encoding Fn14. 
This alteration in Fn14 mRNA is predicted to encode a receptor that is secreted rather than being 
expressed at the cell surface and that lacks domains critical for TWEAK-independent signaling. We 
designed an antisense nucleic acid analog oligonucleotide, morpholino, targeting the predicted 
exonic splicing enhancer sites in exon 3 of Fn14 pre-mRNA. Here we show that transfection of 
this morpholino yields efficient skipping of Fn14 exon 3 in human melanoma cell lines. Reverse 
transcription and cDNA sequencing confirmed that the morpholino prevented splicing of exon 3 
and produced mRNA with the predicted sequence. The resulting mRNA, with in-frame splicing of 
exon 2 to exon 4, encodes a protein lacking a portion of the extracellular domain and entire trans-
membrane domain of the full-length Fn14 protein. Altered RNA splicing leads to downregulation 
of Fn14 protein and loss of Fn14 signaling. The truncated Fn14 is predicted to be secreted and may 
be capable of functioning as a decoy receptor by binding to TWEAK and blocking TWEAK/Fn14 
signaling in a paracrine manner. Thus morpholino-based exon skipping represents an efficient and 
novel means of blocking Fn14 signaling in melanoma.    
621
High expression of Mcl-1 mediated by MEK–ERK1/2–STAT3 signaling pathway protects mela-
nocytes and melanoma cells against ultraviolet B-induced apoptosis
T Fukumoto,1 T Iwasaki,2 T Okada,3 T Hashimoto,2 Y Moon,2 M Sakaguchi,1 Y Fukami,2 
C Nishigori1 and M Oka1 1 Division of Dermatology, Department of Internal Related, 
Kobe University Graduate School of Medicine, Kobe, Japan, 2 Department of Biology, 
Kobe University Graduate School of Science, Kobe, Japan and 3 Division of Biochemistry, 
Department of Molecular and Cellular Biology, Kobe University Graduate School of 
Medicine, Kobe, Japan
The role of Mcl-1, an anti-apoptotic member of Bcl-2 family protein, in ultraviolet (UV) B-induced 
apoptosis in melanocytes and melanoma cells was examined. When melanocytes were irradiated 
with UVB at 50 mJ/cm2, the percentage of apoptotic cells was negligible at 24 h, although many 
cells underwent apoptosis at 48 and 72 h. UVB irradiation induced an increase in Mcl-1 protein, 
Mcl-1 mRNA, ERK1/2 phosphorylation, Ser727 phosphorylation on STAT3, and nuclear trans-
location of STAT3 phosphorylated at Ser727 (pS-STAT3). All of these responses were inhibited 
by MEK inhibitor U0126, concomitant with an increase in apoptosis at 24 h. Inhibition of Mcl-1 
protein expression by Mcl-1 siRNA also resulted in an increase in UVB-induced apoptosis at 24 
h. WM35 and WM39 melanoma cell lines derived from early tumor progression stage expressed 
high levels of Mcl-1 regulated by MEK–ERK1/2–pS-STAT3 signaling pathway and were resistant to 
UVB (50 mJ/cm2)-induced apoptosis even at 72 h. However, UVB irradiation induced apoptosis 
in these melanoma cells when the expression levels of Mcl-1 were reduced by siRNA or U0126. 
Melanoma cell lines expressing low levels of Mcl-1 underwent apoptosis 72 h after UVB irradiation. 
Electrophoretic mobility shift assay using nuclear extracts from WM39 cells revealed a putative 
binding site for pS-STAT3 in the promoter region of the Mcl-1 gene, suggesting that pS-STAT3 acts 
as a transcription factor for the Mcl-1 gene. These results indicate that high expression of Mcl-1 
mediated by MEK–ERK1/2–pS-STAT3 signaling pathway protects melanocytes and melanoma cells 
against UVB-induced apoptosis.    
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Y chromosome encoded TSPY proto-oncogene drives increased melanoma cell aggressiveness 
Z Huang,1 Y Li,1 T Kido,1 I Yeh,1 K Korgavkar,1 A Nosrati,1 J Livingstone,2 JW Wong,2 
G Scott,3 C Lau1, 2 and ML Wei1, 2 1 University of California, San Francisco, CA, 2 Veterans 
Affairs Medical Center, San Francisco, CA and 3 University of Rochester, Rochester, NY
Men with melanoma have poorer outcomes compared to women, even when controlling for tumor 
characteristics such as Breslow thickness/stage, anatomic site, age, metastasis, and treatment. The 
purpose of this study is to assess if a male specific factor, the Y chromosome encoded oncogene 
TSPY, is sufficient to increase tumorigenic properties when aberrantly and ectopically expressed 
in male melanoma cells. Normally, TSPY is expressed only in male germline cells, but it has also 
been found to be aberrantly expressed in somatic cancers occurring in men, such as melanoma, 
and could drive or contribute to a more aggressive tumorigenic growth behavior, compared to 
tumors in women, which lack TSPY expression. Melanocytes from men did not have detectable 
TSPY expression, but 3 of 4 male melanoma cells lines screened did exhibit TSPY expression, while 
none of the female melanoma cells lines expressed TSPY. Nevi, primary melanoma and patient 
matched metastatic melanoma samples from men (and women as negative controls) were probed 
for TSPY; levels of TSPY in men were found to be significantly elevated, by more than 3-fold, in 
primary melanomas compared to nevi (p < 0.05). TSPY was stably expressed ectopically de novo 
via lentivirus in female and male melanoma cell lines, and also overexpressed in TSPY expressing 
male melanoma cells; clones were assayed for growth, motility, invasiveness and sensitivity to 
chemotherapy. Increased expression of TSPY resulted in a 2-3 fold increase in growth at 3 days (p 
< 0.5), an 8-fold increased migration (p < 0.05), a 3-fold increase in invasiveness (p < 0.05), and a 
2-6 fold increase in cisplatin sensitivity (p < 0.05) in both male and female melanoma cells. These 
results support a role for ectopically expressed TSPY contributing to a more aggressive melanoma in 
males, and suggest a molecular mechanism for the poorer clinical outcome in men with melanoma 
compared with women.    
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Broadband light absorption characteristics of melanin: human skin measurement beyond 
Chromameter and Mexameter
I Seo and H Ouyang Johnson and Johnson CPPW, Skillman, NJ
Melanins are a broad class of macromolecule that absorbs light in a broad range of visible and 
ultra-violet radiation. The absorption spectrum of melanin does not have any distinctive absorption 
bands probably due to the overlap of absorption spectra from constituting multiple oligomers. 
The amount of human epidermal melanin is commonly assessed by L* of chromameter or by 
narrow-band diffuse reflectance (Mexameter). However, L* is also affected by other chromophores 
(hemoglobins), and the L* levels can be similar for Caucasians, Eastern Asians, and Hispanics of 
different skin colors. In addition, reflectance in the narrow-band spectrum (red part) is closely cor-
related to L* for different ethnicities. To identify new melanins that help account for the broadband 
absorption, we measured absorption spectra of granular form of melanin in water and supernatants 
of melanin solution after membrane filtration using spectrophotometer. Absorption spectrum for 
melanin granules was linear in wavelength while for soluble melanin the absorption was exponential 
in the blue part with minimal change in the red part spectrum. Investigation of dissolution kinetics of 
melanin granules in water revealed that dissolved fine particles of melanin contributed absorption 
change in the blue part only. To validate the models and method developed in vitro, we analyzed 
diffuse reflectance spectra acquired in vivo from 300 subjects of different ethnicities on their upper 
inner arm and cheek. The amount of soluble melanin was determined by the absorption at the 
blue part spectrum and granular melanin at the red part spectrum. We found that the amount of 
soluble melanin is independent of the amount of granular melanin commonly assessed by L* or 
Mexameter, and the soluble melanin is well correlated to b* but not to L*. We conclude that the 
epidermal melanin of human skin can be better assessed by accounting for the contributions from 
both granular form and soluble form of melanin.    
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CDK1 enhances tumor initiation and stemness by interacting with stem cell genes in human 
cancers
Y Luo,1 JJ Arcaroli,2 N Nguyen,1 S Liu,1 L Kutty,1 S Bagby,2 S Robinson,2 W Robinson,2 
D Norris1, 3, W Messersmith2 and M Fujita1, 3 1 Dermatology, University of Colorado Denver, 
Aurora, CO, 2 Medicine, University of Colorado Denver, Aurora, CO and 3 Denver VA 
Medical Center, Denver, CO
Genes related with enhanced tumor initiating capacities are paramount to advancing our under-
standing of cancer cell biology. Over the last decade, it has become clear that cancers are com-
prised of heterogeneous cell populations with different tumorigenic capacities, phenotypes and 
functions, and that tumor digestion and isolation protocols affect tumor cells by enriching distinct 
tumor subpopulations. In this study, to identify key genes to enhance tumor initiation, we analyzed 
patient-derived xenografts from 6 melanoma, 6 colon and 5 pancreatic cancer tissues using var-
ious experimental digestion and isolation conditions. We found MHC I (HLA)-positive selection 
significantly enriched cells with enhanced tumor initiating capacities. Nanostring® array analysis of 
HLA-positive and -negative tumor cells identified a series of differentially expressed stem cell genes. 
Among them, cyclin-dependent kinase 1 (CDK1) was identified and validated as a significantly 
upregulated gene in HLA-positive tumor cells. HLA upregulation was driven by CDK1 through 
NF-κB activation, and CDK1 promoted tumor growth in mice. Furthermore, CDK1 enhanced clo-
nogenicity in vitro and tumor initiating capacities in vivo, which was not explained by CDK1’s role 
as a master regulator of cell cycles. A proteome array analysis using a CDK1 inhibitor identified 
Snail, an inducer of epithelial to mesenchymal transition, to be positively regulated by CDK1. The 
proteome array analysis also identified the direct interaction of CDK1 and Sox, a pluripotent stem 
cell transcription factor, which was confirmed by Western blotting through immunoprecipitation. 
These findings reveal a novel function of CDK1 in regulating tumor initiating capacity and stem-
ness by interacting with stem cell genes in tumor cells. CDK1 thus serves as a molecular target for 
therapeutic intervention of cancer.    
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Akt activation promotes the development of brain metastases in a mouse model of melanoma
J Cho,1 J Robinson,2 R Arave,7 R Green,1 D Kircher,1 G Chen,3 M Davies,3 A Grossmann,4 
M VanBrocklin5, 6 and S Holmen1, 5, 6 1 Dept. of Oncological Sciences, University of Utah, 
Salt Lake City, UT, 2 Hormel Institute, University of Minnesota, Austin, MN, 3 Dept. of 
Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 
TX, 4 Dept. of Pathology, University of Utah, Salt Lake City, UT, 5 Huntsman Cancer Institute, 
Salt Lake City, UT, 6 Dept. of Surgery, University of Utah, Salt Lake City, UT and 7 Dept. of 
Bioengineering, University of Utah, Salt Lake City, UT
Brain metastases are a major cause of melanoma-related mortality and morbidity. The molecular 
mechanisms driving melanoma brain metastasis remain unclear, thus adding to the difficulties in 
both treating and prognosticating risk for this disease. Several studies have implicated aberrant AKT 
signaling in melanoma progression and metastasis to the brain. Using an established melanoma 
mouse model based on a somatic cell retroviral gene delivery system, we expressed activated Akt1 
in non-metastatic BrafV600E; Ink4a/Arf null murine melanomas. Expression of activated Akt1 resulted 
in highly metastatic melanomas with lung and brain metastases in 67% and 17% of our mice, 
respectively. In contrast to activated Akt1 expression, the loss of Pten in the context of BrafV600E; 
Ink4a/Arf null melanomas did not yield a metastatic phenotype. However, combined Pten loss and 
Akt1 expression in BrafV600E; Ink4a/Arf null melanomas resulted in a higher percentage of brain 
metastases (79% of our mice) and decreased tumor latency, implying a cooperative effect. These 
results demonstrate that in melanomas driven by mutant BrafV600E and Ink4a/Arf loss, activation of 
Akt1 is sufficient to induce brain metastases. Moreover, our data reveal a distinct difference between 
Akt1 activation and Pten loss in terms of metastatic potential and may provide valuable insights 
for clinical treatment and risk assessment for the development of melanoma brain metastases.   
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Phenformin as a therapeutic adjunct for melanoma
FM Shaw1, 2, LC Cantley3 and JH Zippin2 1 Emory University School of Medicine, Atlanta, GA, 
2 Dermatology, Weill Cornell Medical College, New York, NY and 3 Meyer Cancer Center, 
Weill Cornell Medical College, New York, NY
Approximately 2% of the US population will be diagnosed with melanoma during their lifetimes. 
While most cases are successfully treated with surgery, once melanoma metastasizes (4% of cases) 
the five-year survival rate is only 16%. A major molecular pathway involved in melanoma patho-
genesis is the mitogenic MAP kinase (Ras/Raf/MEK/ERK) signaling cascade. It is estimated that over 
50% of melanomas contain a BRAF mutation (V600E) that leads to constitutive MAPK signaling. 
While the current first-line therapy for BRAF V600E mutant melanomas is BRAF inhibitors such as 
vemurafenib and dabrafenib, many tumors develop resistance to these drugs. Aside from melanomas 
harboring BRAF mutations, the remainder of melanomas are BRAF wildtype and therefore are not 
candidates for BRAF V600E inhibitor therapy. Biguanides are a class of drugs originally developed 
for the treatment of diabetes that have shown promise as a potential therapy for melanoma. Prior 
research has demonstrated that biguanides (such as phenformin) prevent melanoma growth via 
activation of AMPK (AMP-activated protein kinase) and lead to synergistic inhibition of cell viability 
in BRAF V600E mutant cell lines when combined with a BRAF inhibitor. We examined the effects 
of phenformin on melanoma growth both alone and in combination with vemurafenib and have 
replicated prior findings that phenformin enhances the effects of vemurafenib in BRAF V600E mutant 
melanoma cells that are sensitive to BRAF inhibitors. In addition, we now show that phenformin 
alone or in combination with other MAPK inhibitors is effective at inhibiting the growth of BRAF 
V600E mutant melanoma cells that are resistant to vemurafenib, as well as melanoma cells that 
do not harbor a BRAF V600E mutation. Overall, these data suggest that phenformin can enhance 
the therapeutic effects of multiple MAPK inhibitors and could serve as a therapeutic adjunct for 
melanomas with a wide range of driver mutations.    
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MicroRNA approach to target collagen recycling, cellular senescence and melanin produc-
tion in vitro
L Mur, F labarrade, C Gondran, G Oberto, Y Ferreira, K Cucumel and N Domloge Ashland 
Specialty ingredients, Sophia Antipolis, France
Skin aging is a complex and continuous process caused by intrinsic factors and extrinsic factors, 
characterized by wrinkles and pigmentation disorders. Among the major changes occurring during 
skin aging, we usually consider the disturbance of collagen metabolism, the slow-down of cell 
turnover and the perturbation of melanin production and distribution. Thereby, the regulation of 
these different processes is crucial to better understand and investigate skin aging. Discovered this 
last decade, miRNAs play a fundamental role in post-transcriptional inhibition of gene expression. 
We focused our work on miRNA-29a which targets different key genes involved in aging and 
more specifically on matrix production such as collagen, collagen I and prolidase (enzyme that 
regenerates the pool of proline, thereby allowing the synthesis of new collagen). We studied also 
the increase of miRNA-218 expression induces a decrease in melanin content via the inhibition 
of MITF expression. MiRNA levels were evaluated by qPCR. First, on in vitro treated fibroblasts 
a decrease in miRNA-29a expression and a positive modulation of collagen and prolidase levels 
were observed. Next, to mimic the cellular senescence, we used an in vitro patented senescent 
model by means of FOXO3a-specific siRNA. We observed, on senescent fibroblasts treated with 
the biofunctional, fewer aging effects on the collagen production cycle. To pursue this study, we 
evaluated miRNA-218 expression on melanocyte cultures: the increase in miRNA-218 expression 
observed on treated melanocytes was linked to a decrease in melanin production. This result was 
confirmed by Fontana Masson staining on ex vivo skin. Finally, to reinforce the in vitro results, a 
clinical test was performed on Asian skin to assess the biofunctional effect on wrinkle appearance 
and skin lightening. Our present results suggest that miRNA expression is fundamental to regulate 
the different key processes perturbed during aging in ex vivo model. Its modulation might help 
minimize some visible effects of aging.    
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Post-translational mechanisms regulate fn14 expression and signaling in melanoma
KM Beck1, 2 and MS Hayden1, 2 1 Dermatology, Columbia University College of Physicians & 
Surgeons, New York, NY and 2 Microbiology & Immunology, Columbia University College of 
Physicians & Surgeons, New York, NY
The surface receptor fibroblast growth factor-inducible 14 (Fn14) and its cognate ligand, TNF-like 
weak inducer of apoptosis (TWEAK), play an important role in inflammation and tissue regeneration. 
As a potent inducer of pro-survival and pro-inflammatory signaling pathways, the TWEAK/Fn14 
axis is widely implicated in the pathogenesis of chronic inflammatory and oncological diseases, 
including melanoma. Fn14, which is poorly expressed in normal tissue including melanocytes, is 
highly expressed in melanoma. We previously reported that Fn14 expression is regulated through 
post-translational receptor trafficking and, therefore, hypothesized that elevated Fn14 expression 
levels in melanoma are due to altered receptor turnover. Using real-time PCR and Western blotting, 
we found marked discordance between Fn14 mRNA and protein levels in human melanoma cell 
lines, suggesting that protein levels are only partially dependent on transcription of Fn14 mRNA. 
Furthermore, analysis of Fn14 half-life in melanoma demonstrates changes in Fn14 dynamics. Over-
expression of Fn14 can cause ligand-independent activation of pro-survival pathways, including the 
NF-κB pathway, and we, therefore, also examined the relationship between Fn14 expression and 
NF-κB activation in the presence and absence of TWEAK. These findings demonstrate the impor-
tance of post-translational mechanisms in governing Fn14 expression and signaling in melanoma.   
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mTOR and PKM2 are constitutively up-regulated in human melanoma cells but not in 
melanocytes
A Gonzalez,1 J Justiniano,1 R Garrity,1 Y Cui2 and Y Wan1 1 Providence College, Providence, 
RI and 2 Northwest University, Xi’an, China
Melanoma is considered one of the most aggressive and less treatable cancers. While various 
models and mechanisms have been proposed, the transformation from tranquil melanocytes to 
invasive melanoma cells remains an enigma. Pyruvate kinase M2 has been shown to be an important 
constituent of the Warburg effect (a hallmark of cancer) and an increase of this kinase correlates 
with increased glycolysis and an up-regulated mTOR pathway. Despite constituent activation of 
the mTOR/AKT pathway in melanoma cells, it is still not known whether pKM2 is up-regulated 
upon melanocyte transformation to melanoma. In order to study PKM2, we compared the cellular 
response to α-melanocyte stimulating hormone (or α-MSH) in both primary human melanocytes 
and melanoma (WM 266-4 Cell line). Both types of cells were treated with α-MSH. Immunoblots 
and confocal microscopy were used to visualize the activity of mTOR and pKM2 at different time 
points after treatment. Our results showed that α-MSH activates mTOR pathway in both human 
melanocytes and melanoma cells, while melanoma cells exhibit constitutive activation of mTOR. 
We found that PKM2 is also constitutively up-regulated in melanoma cells. Interestingly, our exper-
iments did not show a change in the level of phosphorylation of PKM2 in both types of cells in 
response to α-MSH treatment.    
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Circadian rhythm of human tyrosinase
EC Goyarts and N Pernodet Estee Lauder Companies, Melville, NY
To determine if tyrosinase transcription is following a rhythm encompassing a 24h time interval, 
two methods of melanocyte entrainment were explored. Melanocytes were entrained through the 
removal of growth factors or by the addition of dexamethasone to hydrocortisone-free media. Star-
vation, which begins cells in the night phase, entrained them for about 6h and generated a strong 
induction of the clock gene, PER2. A short exposure to dexamethasone was sufficient to entrain 
the cells for more than 24h. With these two methods, we observed that transcription of human 
tyrosinase follows a circadian rhythm with a peak at night, between 8-10 PM. A 35% increase in 
tyrosinase transcription was determined when melanocytes were unsynchronized and compared 
to synchronized cells in a 6 hour time interval. This is in good agreement with the increase in 
pigmentation observed during aging or through the lack of sleep.    
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Characteristic comparison of human melanoma cell lines derived from primary and met-
astatic sites
X Lin,1 D Fiore,1 P Thompson,1 JK Goodrich,1 T Yufit,1 P Carson1 and V Falanga1, 2 1 
Dermatology, Boston University School of Medicine, Boston, MA and 2 Biochemistry, Boston 
University School of Medicine, Boston, MA
Human primary and metastatic melanoma may have distinct biological and clinical characteris-
tics. Blood and vascular supply may be an important factor for solid tumor cell survival. Here we 
examined serum depletion’s effect on two unique melanoma cell lines: WM-115, derived from a 
primary tumor, and WM-266-4, derived from a metastatic site of the same primary tumor from the 
same patient. We tested cell attachment, proliferation and migration properties of the two cell lines 
in MEM medium, with either10%, 1%, or 0.1% fetal bovine serum (FBS). Attachment of cells was 
determined after incubation for 30 minutes in standard tissue culture plates at 37oC. Cell proliferation 
was monitored for 72 hours using a ViaLight Plus High Sensitivity Cell Proliferation/Cytotoxicity 
Kit. For the migration assay, we utilized a novel research tool called IncuCyte, which enables time-
lapse cell photography in a standard incubator, along with a specialized wound-scratch module 
that makes uniform scratches in the cell monolayer. We found that cell attachment, proliferation 
and migration of the WM-266-4 cell line, derived from the metastatic site, were more responsive 
to the decrease of FBS concentration compared to the WM-115 cell line. Therefore, the WM-266-4 
cell line showed a statistically significant decrease in the rate of attachment and migration as the 
FBS was lowered from 10% to 1% (p<0.05), while the WM-115 cell line showed no statistically 
significant difference (p>0.05). For the proliferation assay, the lowering of FBS concentration from 
10% to 1% or 0.1% greatly decreased the proliferation rate at 48 hours in the WM-266-4 cell line 
compared to the WM-115 cell line (p<0.05). Our results suggest that critical biological differences 
between the two unique melanoma cell lines exist, and add information to the understanding of 
human solid tumors in primary and metastatic sites.    
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Effects of MAPK inhibition on glucose uptake in melanoma are largely secondary to alterations 
in cellular morphology 
N Theodosakis,1 MA Held,1 A Marzuka1 and M Bosenberg1, 2 1 Pathology, Yale School of 
Medicine, New Haven, CT and 2 Dermatology, Yale School of Medicine, New Haven, CT
In 2011, the FDA approved the mutant BRAF inhibitor vemurafenib for treatment of metastatic 
melanoma harboring V600 activating BRAF mutations. Within weeks of therapy, the 18FDG-PET 
tumor signal, which corresponds to the rate of glucose uptake relative to normal tissue, is dra-
matically reduced in the majority of BRAF-mutant tumor patients. Unfortunately, almost 100% of 
tumors acquire resistance to BRAF inhibitors wiithin 18 months, with evolution of resistance against 
second-line MEK inhibitors shortly thereafter. Because MAPK is known to control multiple aspects 
of tumor metabolism, the direct effect of MAPK inhibitors on glucose utilization is an important 
field of study. Using flow cytometry and the fluorescent deoxyglucose analog 2-NBDG, we have 
observed a rapid decrease in glucose uptake in vemurafenib-sensitive human melanoma cell lines in 
vitro that is not observed in resistant lines and is rapidly reversible with drug removal. Investigation 
of the mechanism of this uptake loss by flow cytometry and Coulter Effect measurement shows that 
changes in cell volume are a primary determinant of the decrease of glucose uptake on a per cell 
basis. We have also shown that this relationship can be independently verified by manipulating 
cell size through altering media tonicity. In the setting of BRAF inhibition, our studies suggest that 
cell size decrease is likely mediated by a decrease in global protein translation, with direct inhi-
bition of translation showing similar effects on volume and glucose uptake in vemurafenib-naïve 
cells. We have also observed similar effects of BRAF inhibition on cell size in a cohort of matched 
pre- and post-treatment biopsies obtained from human metastatic melanoma patients undergoing 
BRAF inhibitor therapy. Overall, our study suggests that alterations in cellular volume significantly 
contribute to decreases in 18FDG-PET signal immediately following treatment, and may in part 
explain the relatively rapid reappearance of metastases at original sites when resistance occurs.   
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Correlation of insulin-like growth factor II mRNA-binding protein 3 (IMP-3) and high mobility 
group AT-hook 2 (HMGA2) expressions in human melanoma
C Chu, Y Sheen, C Yeh and S Jee Department of Dermatology, National Taiwan University 
Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
Insulin-like growth factor II mRNA-binding protein 3 (IMP-3) has been reported to be a novel 
marker of melanoma progression. However, the mechanisms by which it impacts melanoma are 
incompletely understood. We found that IMP-3 could bind and enhance the stability of the mRNA 
of HMGA2. It was also confirmed that IMP-3 played an important role in melanoma invasion and 
metastasis through regulating HMGA2 mRNA expression. A total of 97 patients with primary cuta-
neous melanoma at the National Taiwan University Hospital diagnosed between January 1995 and 
November 2009 were enrolled. Immunohistochemical examination of human melanoma tissues 
demonstrated that tumor cells with high IMP-3 levels also had high HMGA2 expression, while those 
with low IMP-3 levels had weak or negative HMGA2 expression. A positive correlation of IMP-3 
and HMGA2 expressions in melanoma was found (P = 0.003). qRT-PCR of melanoma tissues from 
25 patients also showed a strong positive correlation between IMP-3 and HMGA2 mRNA levels. 
Pearson correlation measurement gives the result 0.95. In addition, only 14.4% of melanoma 
patients had BRAF V600E/V600K and that only 12.4% had NRAS Q61R/Q61L/Q61H/G13D muta-
tions in this study. HMGA2 overexpression was not associated with BRAF or NRAS mutations in 
our study population. The above results indicate that HMGA2 expression in our melanoma patients 
is regulated by IMP-3 rather than by BRAF/NRAS mutations.    
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Multigene epigenetic signature is a prognostic marker in melanoma
G Micevic,1 V Muthusamy,1 R Scolyer2 and M Bosenberg1 1 Yale School of Medicine, New 
Haven, CT and 2 Melanoma Institute of Australia, Sydney, NSW, Australia
The purpose of this study is to develop more accurate survival prognostic approaches for melanoma 
patients, who currently exhibit great variability in survival even within AJCC sub-groups. Aberrant 
promoter DNA methylation is a key epigenetic feature of cancer and identification of a DNA 
methylation signature (CpG island methylator phenotype), has been useful in predicting prognosis, 
diagnosis and response to treatment in a variety of tumor types. In this study, we define a methylation 
based melanoma survival prognostic score, MethyLive. We used a discovery set of 14 melanoma 
tumor samples derived from patients and sub-divided it into two sets on the basis of overall survival. 
We examined promoter methylation status of 70 genes using bisulfite modification, PCR and Sanger 
sequencing. Differentially methylated candidate genes were used to build a survival prediction 
score, MethyLive, by multiple regression modeling using a training cohort of melanoma patients 
from The Cancer Genome Atlas (TCGA). In the validation cohort, a high MethyLive score was asso-
ciated with a significantly longer recurrence free survival (p=0.004, HR ) and longer overall survival 
(p=0.0007) in Stage III, Stage IIIc (p=0.01), and melanoma patients of all stages (p<0.0001) from 
The Cancer Genome Atlas. The significance of MethyLive is improved stratification of patients with 
favorable and poor outcomes within AJCC sub-groups. E.g. MethyLive identified Stage IIIc patient 
sub-groups with 70% and 20% ten year overall survival, providing significantly more information 
than the AJCC Stage IIIc general 10-year overall survival of 24%. Improved prognostic accuracy 
can contribute to improved care of melanoma patients and provision of most appropriate therapies.   
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Delayed cyclobutane pyrimidine dimers induced by chemiexcited melanin derivatives long 
after UV exposure
S Premi,1 S Wallisch,1 C Mano1, 2, A Weiner,1 A Bacchiocchi,3 K Wakamatsu,4 E Bechara2, 
5, R Halaban3, 6, T Douki7 and DE Brash1, 6 1 Therapeutic Radiology, Yale Univ. School 
of Medicine, New Haven, CT, 2 Dept. de Bioquímica,, Univ. de São Paulo, Sao Paulo, 
Brazil, 3 Dermatology, Yale Univ. School of Medicine, New Haven, CT, 4 Chemistry, Fujita 
Health Univ., Toyoake, Japan, 5 Dept. de Ciências Exatas e da Terra, Univ. Federal de São 
Paulo, São Paulo, Brazil, 6 Yale Comprehensive Cancer Center, Yale School of Medicine, 
New Haven, CT and 7 Commissariat a` l’Energie Atomique, INAC/LCIB UMR-E3 CEA-UJF, 
Grenoble, France
Cyclobutane pyrimidine dimers (CPD) are created nearly instantaneously as the energy of a UV 
photon is absorbed by DNA. Melanoma is etiologically associated with CPD generated by sunlight 
exposure. Melanin acts as shield for sunlight’s UV; however UVA irradiated mice develop melanoma 
only if their melanocytes contain melanin. To investigate this paradox, we studied repair of UV 
induced CPD in human and mouse melanocytes. Surprisingly, CPD were created in melanin-con-
taining melanocytes for hours after an initial UV exposure. The same was true for keratinocytes in 
vivo that received the melanin from melanocytes. These “delayed” or “dark” CPD also included 
cytosine-containing CPD which initiate UV-signature CÇT mutations. In vivo, the skin from mice 
with yellow fur showed even higher accumulation of dark CPD compared to skin from mice with 
black fur. Knocking down Xpc and Xpa transcripts revealed the dark CPD which were masked by 
excision repair in primary human melanocytes from some donors. We identified a novel pathway 
whereby reactive oxygen and nitrogen species oxidize UV-fragmented melanin and generate a 
melanin carbonyl in a triplet quantum state. This melanin carbonyl contains energy equivalent to 
a UV photon and generates CPD by radiationless energy transfer to DNA. This result suggests that 
melanin is carcinogenic as well as protective against cancer. It also validates the importance of 
chemically excited species in mammalian biology. Screening for novel triplet quenchers to develop 
“evening-after” sunscreens could potentially prevent the carcinogenic processes transpiring in skin 
hours after sun exposure ends.    
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Oncogene starvation via selective CDK7 inhibition: A novel approach for targeting tradition-
ally undruggable oncogenic molecules in melanoma
P Eliades1, 2, DM Miller,1 M Taylor,1 R Kumar,1 N Kwiatkowski,3 T Zhang,4 RA Young,3 
NS Gray4 and H Tsao1 1 Wellman Center for Photomedicine and Dept of Dermatology, 
MGH, Boston, MA, 2 Tufts University School of Medicine, Boston, MA, 3 Whitehead Institute 
for Biomedical Research, MIT, Cambridge, MA and 4 Dept of Biological Chemistry and 
Molecular Pharmacology, HMS, Boston, MA
Cyclin-dependent kinase 7 (CDK7), a unique member of the CDK family, has garnered attention 
as an anti-cancer target given its regulatory roles in the cell cycle and RNA polymerase (RNAP) 
II’s transcriptional machinery. Interestingly, it has been shown that selectively targeting CDK7 
with THZ1 (3.2nM IC50), a covalent CDK7 inhibitor, causes preferential downregulation of critical 
oncogenes, especially those associated with super-enhancers. Here, we present novel, preclinical 
results of THZ1 in melanoma. A panel of genotypically-diverse human melanoma cell lines treated 
with THZ1 demonstrated exquisite sensitivity, with GI50 values ranging from 5 to 100nM. Cell 
cycle and apoptosis assays of representative cutaneous and uveal melanoma cell lines treated 
with THZ1 revealed sub-G1-phase arrest and a robust induction of apoptosis when compared to 
DMSO-treated controls (p<0.001). Immunoblotting confirmed that THZ1 abrogated CDK7-specific 
RNAP II phosphorylation (Rpb1 Ser5/7) and CDK7’s CDK-activating kinase (CAK) function. We 
found that THZ1 strongly reduced the protein and mRNA levels of the master oncogene, MITF, in 
several melanoma lines, including one with a documented super-enhancer complex at the MITF 
locus. Additionally, overexpressing MITF with a doxycycline-inducible transgene system increased 
melanoma cell resistance to THZ1. We are currently utilizing chromatin immunoprecipitation 
coupled to high-throughput sequencing (ChIP-seq) to examine THZ1-mediated disruption of RNAP 
II occupancy at the MITF locus. In vivo efficacy studies using a murine xenograft model are also 
ongoing. In summary, THZ1 is one of the most potent anti-melanoma drugs tested in vitro and rep-
resents a novel class of therapeutic inhibitors able to mediate “oncogene starvation” in melanoma.   
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Sex steroids regulate human pigmentation through non-classical receptors
C Natale and TW Ridky Dermatology, University of Pennsylvania, Philadelphia, PA
Human pregnancy and oral contraceptive use are commonly associated with altered epidermal pig-
mentation, suggesting that changes in circulating hormones may regulate melanocyte homeostasis. 
However, the specific hormones, receptors, and downstream pathways mediating these effects are 
largely undefined. We demonstrate that physiologically relevant levels of 17β-estradiol (estrogen) 
promotes pigment production, while progesterone has opposing effects. Altered melanin production 
is associated with parallel changes in cAMP, a known regulator of mammalian pigmentation. The 
mechanisms through which sex steroids regulate melanin production are particularly intriguing, 
given that normal primary melanocytes do not express the classical estrogen and progesterone recep-
tors (ER/PR). Here we show that melanocytes express the nonclassical steroid hormone receptors 
G protein-coupled estrogen receptor 1 (GPER1), and Progestin and AdipoQ Receptor 7 (PAQR7). 
Lentiviral-mediated CRISPR-Cas9 ablation of these proteins blocks the pigmentary effects of estro-
gen and progesterone, suggesting that estrogen and progesterone reciprocally affect pigmentation 
through the nonclassical receptors GPER1 and PAQR7, respectively, to regulate human melanocyte 
homeostasis. Modulation of these receptors and their associated signaling pathway elements may 
have therapeutic utility in disorders of epidermal pigmentation.    
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Fisetin potentiates the anti-invasive and anti-metastatic effects of sorafenib in BRAF-mutated 
melanoma
HC Pal,1 AC Diamond,1 JC Kappes,2 CA Elmets1 and F Afaq1 1 Dermatology, University 
of Alabama at Birmingham, Birmingham, AL and 2 Medicine, University of Alabama at 
Birmingham, Birmingham, AL
Melanoma is responsible for approximately 80% of all skin cancer-related deaths due to its propen-
sity to metastasize. BRAF, the most commonly mutated oncogene in melanoma, drives sustained 
activation of the BRAF/MEK/ERK (MAPK) pathway and cooperates with PI3K/AKT/mTOR (PI3K) 
signaling, which induces epithelial to mesenchymal transition (EMT) and enhances cell invasion and 
metastasis. Therefore, targeting the MAPK and PI3K signaling pathways may be a promising strategy. 
Fisetin, a phytochemical, possesses anti-proliferative, pro-apoptotic and anti-tumor activities. Earlier, 
we showed that treatment of human melanoma cells with fisetin decreased cell invasion. In addition, 
fisetin inhibited tumor growth by downregulating the PI3K/AKT/mTOR signaling pathway. Here, 
we investigated the effects of fisetin and sorafenib (a RAF inhibitor), alone and in combination on 
cell migration, invasion and metastasis. We found that combination (fisetin + sorafenib) treatment 
more effectively reduced the migration and invasion of BRAF-mutated melanoma cells both in vitro 
and in raft cultures when compared to individual agents. Furthermore, the combination treatment 
synergistically inhibited EMT, as observed by the reduction in mesenchymal markers (N-cadherin, 
vimentin, fibronectin, snail, twist and slug) and the increase in epithelial markers (E-cadherin and 
desmoglein) both in vitro and in xenograft tumors. Bioluminescent imaging of athymic nude mice, 
intravenously injected with stably transfected CMV-luciferase-ires-puromycin.T2A.EGFP-tagged 
BRAF-mutated A375 human melanoma cells, demonstrated significantly fewer lung metastases 
following combination treatment versus monotherapy. Our findings have demonstrated fisetin’s 
ability to potentiate the anti-invasive and anti-metastatic effects of sorafenib, in vitro and in vivo. 
Evolving evidence suggests this minimally toxic compound may be a worthy adjuvant chemotherapy 
for the management of melanoma.    
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P2X7/PANX1 inhibition decreases melanoma proliferation and differentiation in vitro and 
decreases tumor growth in vivo
J Bordelon,1 SL Schneider1, 4, AL Ross,1 M Eller1 and JM Grichnik1, 2, 3 1 Department of 
Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, 
FL, 2 Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 
Miami, FL, 3 Interdisciplinary Stem Cell Institute, University of Miami Miller School of 
Medicine, Miami, FL and 4 Albert Einstein College of Medicine, Bronx, NY
Metastatic melanoma is lethal for most patients, likely because of tumor cells resistant to targeted 
therapies. The role that inflammasomes, multi-protein complexes involved in inflammation, play 
in melanoma is becoming increasingly recognized yet not fully understood. PANX1 and P2X7 
are ATP-regulated, plasma membrane channels that act synergistically to regulate inflammasomal 
activity. Brilliant Blue G (BBG) and probenecid (P) inhibit P2X7 and PANX1 respectively, so we 
explored using these agents to study the effect of inflammasomal inhibition in melanoma. Western 
blot, immunofluorescence, and FACS found that inhibition of P2X7/PANX1 by BBG/P decreased 
MITF (a marker of differentiation) and Ki67 (a marker of proliferation) levels suggesting a transi-
tion to a less proliferative and less differentiated state in vitro. We also examined the effect of a 
P2X7-specific monoclonal antibody (L4) on melanoma differentiation/proliferation. Using L4, cells 
were sorted into P2X7-high or -low populations. Lower MITF expression in P2X7-low cells was 
consistent with the effect of P2X7 inhibition. In order to study the effects of BBG/P in vivo, nude 
mice (6 per group) were injected with melanoma cells and treated daily with high or low dose 
BBG or P, or combinations of each. Tumor growth was followed and weights calculated at the 
experimental endpoint. Due to small numbers and variability no arm alone reached significance; 
however the combination of treated arms was significant compared to the control (p<0.017). The 
high dose combination group showed the greatest impact on tumor size. Together, these findings 
suggest that inflammasomal modulation may impact melanoma growth and differentiation in vitro 
as well as tumor growth in vivo.    
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Notch1 confers melanoma resistance to temozolomide through NLRP1 upregulation
Z Zhai,1 W Liu,1 M Kaur,1 Y Luo,1 D Norris1, 3, RA Spritz,2 CA Dinarello2 and M Fujita1, 3 1 
Dermatology, University of Colorado AMC, Aurora, CO, 2 Medicine, University of Colorado 
AMC, Aurora, CO and 3 Denver VA Medical Center, Denver, CO
Activated NF-κB transcription factor and the resultant release of active IL-1β play important roles 
in melanoma survival, tumorigenesis and metastases. The processing of bioactive IL-1β involves 
inflammasome-dependent caspase-1 activation. Our previous studies have demonstrated an auto-
crine mechanism that promotes constitutive activation of inflammasome and secretion of IL-1β, and 
NLRP1 inflammasome as an NF-κB activator and a tumor promotor in metastatic melanoma. Activa-
tion of NF-κB confers melanoma resistance to temozolomide (TMZ), an alkylating agent used to treat 
metastatic melanoma. Herein, we assessed the role of NLRP1 in TMZ chemoresistance in human 
melanoma. TMZ treatment of metastatic melanoma 1205Lu cells resulted in decreased cell prolif-
eration in vitro and suppressed tumorigenesis in vivo, accompanied by increased NLRP1 expression 
in vitro and in vivo. NLRP1 silencing in 1205Lu and metastatic melanoma HS294T cells attenuated 
TMZ-induced IL-1β secretion, but enhanced TMZ-mediated cell growth inhibition. 1205Lu and 
HS294T cells were cultured with an increasing dose of TMZ for 2-3 months, and TMZ-resistant 
cells were established. When compared to parental 1205Lu and HS294T cells, TMZ-resistant cells 
showed increased NLRP1 expression and IL-1β secretion. However, NLRP1 silencing could partially 
reverse the sensitivity of resistant 1205Lu and HS294T cells to TMZ, and TMZ in vitro enhanced 
Notch1 signaling in resistant 1205Lu and HS294T cells. To understand the relationship among 
Notch1, NLRP1 and IL-1β secretion, cells were treated with Notch 1 inhibitor, NLRP1 silencing 
or IL-1Ra. Whereas Notch1 inhibitor DAPT inhibited TMZ-induced NLRP1 expression and IL-1β 
secretion, IL-1Ra had no influence on TMZ-induced Notch1 expression, and silencing NLRP1 did 
not alter Notch1 expression. These findings demonstrate that Notch1 confers melanoma resistance 
to TMZ and that NLRP1 is an effector downstream of Notch1 signaling.    
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Narrow band UVB treatment of human vitiligo is associated with induction of stem cell genes 
for melanocyte repopulation in the hair follicle and epidermis
NB Goldstein,1 MI Koster,1 L Hoaglin,1 B Gao,2 K Jones,3 DR Roop,1 D Norris1 and SA Birlea1 
1 Dermatology, University of Colorado, Aurora, CO, 2 Genomics Core, University of 
Colorado, Aurora, CO and 3 Biochemistry, University of Colorado, Aurora, CO
Using fluorescent marker immunostaining, we have identified the melanocyte (MC) populations that 
emerge from the hair follicle (HF) bulge during narrow band UVB (NBUVB) treatment for human 
vitiligo. After exiting the HF bulge, these populations proliferate, migrate, and differentiate along 
the HF outer root sheath (ORS), and repopulate the interfollicular epidermis (IE) with mature MCs. 
Our next aim was to identify the gene expression profiles in the depigmented skin of 3 untreated 
vitiligo patients and repigmented skin of 3 vitiligo patients treated 4 months with NBUVB. Using 
laser capture microdissection of frozen immunostained transverse sections, we harvested 100 single 
MCs, and separately 100 adjacent keratinocytes (KCs) from both basal epidermis and ORS of the HF 
bulge. Total RNA was extracted, amplified, and subjected to whole transcriptome RNA sequencing. 
Gene expression values in the MCs of treated versus untreated bulge and of treated bulge versus 
treated IE were compared. With this technique we had remarkable segregation of MC-specific genes 
(DCT, TYR, TYRP1, MLANA, PMEL, PAX3, KIT), versus KC-specific genes (KRT5, KRT10, KRT14, 
KRT15, KRT16, DSG3). In the bulge MC, NBUVB treatment upregulated expression of stem cell 
genes, the top differentially expressed (1E-04 < P < 5E-02) being NCAM1 (9-fold increase) and HES1 
(4-fold increase). In the UV-treated bulge MC, stem cell genes like MME, FZD7, NCAM1 (each > 
99-fold increase), and WNT4 (390-fold decrease), were the top differentially expressed (1E-04 < 
P < 5E-02), as compared to treated IE. Our results validate this approach to identify and study HF 
bulge MC stem cell populations, the apparent source of epidermal repigmentation in vitiligo. These 
techniques are now being used to fully characterize the gene expression profiles of MCs and KCs 
during vitiligo treatment, to identify better ways to produce repigmentation.    
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Tyrosinase targeting self-delivering RNAi compounds
M Maxwell, K Holton, J Cardia, L Pandarinathan, M Byrne and K Bulock RXi Pharmaceuticals, 
Marlborough, MA
Malignant melanoma is the most aggressive form of skin cancer. It typically originates in melano-
cytes located in the epidermis’ stratum basale. Melanoma arises in part due to abnormal melanin 
biosynthesis and in its more aggressive state is often resistant to standard forms of chemotherapy. 
Melanin biosynthesis begins with the oxidation of L-tyrosine to L-DOPA followed by further oxi-
dation of L-DOPA to dopaquinone. These reactions are the rate limiting steps in melanin synthesis 
and are catalyzed by the same tyrosine hydroxylase enzyme, Tyrosinase (TYR). Recently, it has 
been demonstrated that inhibition of Tyrosinase activity increased sensitivity to standard chemo-
therapeutic agents, resulting in decreased cell viability in pigmented melanoma cell lines. For 
this reason, Tyrosinase is an attractive target for RNAi gene silencing. We have developed a new 
class of stable, self-delivering RNAi compounds (sd-rxRNA®) that incorporate features of RNAi 
and antisense technology. These sd-rxRNAs demonstrate potent activity, stability, and reduced 
immune stimulation and are rapidly and efficiently taken up by cells without the requirement of 
a transfection reagent or delivery vehicle. Our goal is to use the sd-rxRNA platform to develop an 
RNAi compound targeting Tyrosinase as a potential therapeutic for the treatment of melanoma and 
other dermatological indications. Tyrosinase-targeting sd-rxRNAs were designed, synthesized and 
screened in the skin melanoma cell line SK-MEL-5 to identify potential lead compounds. For the in 
vitro screens, the SK-MEL-5 cells were treated with sd-rxRNAs for 48 hours, after which Tyrosinase 
mRNA levels were analyzed by both qPCR and the branched DNA Assay (bDNA). The results of the 
preliminary screen resulted in five (5) sd-rxRNAs that demonstrated a dose dependent reduction in 
Tyrosinase mRNA expression. Further chemical optimization of these lead sd-rxRNAs and additional 
phenotypic characterization is currently ongoing. An update, including in vitro effects on protein 
content and effects in skin equivalents with melanocytes, will be provided.    
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Differences in patient and tumor characteristics in amelanotic vs. pigmented melanomas
LC Strazzulla,1 X Li,3 L Tong,2 SJ Lee3 and CC Kim4 1 NYU Medical School, New York, NY, 
2 UCLA Medical School, Los Angeles, CA, 3 Biostatistics, Dana-Farber Cancer Institute, 
Harvard Medical School, Boston, MA and 4 Dermatology, Beth Israel Deaconess Medical 
Center, Harvard Medical School, Boston, MA
Clinically amelanotic melanomas (AM) can be difficult to identify, often leading to late diagnosis and 
poor outcomes. Little is known about patients at risk for AM. This study aimed to identify differences 
in patient and tumor characteristics in AM vs. pigmented melanoma (PM). A retrospective review of 
medical records of patients with a diagnosis of melanoma seen in the BIDMC melanoma program 
over one year was performed with IRB approval. Chi Square or t-test was used in the analysis and 
2-sided p-values are reported. In all, 258 patients had known clinical and pathologic data: 71(28%) 
had AM, defined as not having brown pigment, and 187(72%) had PM. Importantly, 20% of AM 
were reportedly not identified by initial medical exam, compared to 6% of PM (p<.001). Mean age 
at diagnosis was older (p=.004) for AM (51.6 years, se=1.8) vs. PM (45.9 years, se=1.0). Patients 
with AM were more likely to have had a non-melanoma skin cancer vs. patients with PM (38% vs. 
20%, p=.002) and less likely to have atypical nevi (38% vs. 53%, p=.032). A higher proportion of 
AM patients had a history of immunosuppression or malignancy vs. PM (27% vs. 15%, p=.029). 
Mean Breslow depth was deeper for AM vs. PM (2.1 mm, se=0.3, range: 0.14-15 vs. 1.5 mm, se=0.1, 
range: 0.23-13, p=.035). AM were less likely to be classified as superficial spreading than PM (38% 
vs. 61%, p=.001), with a higher proportion of nodular subtype (17% vs. 8.5%, p=.075). In addition, 
AM were less likely to present with a precursor lesion (20% vs. 40%, p=.007) and the mitotic rate 
trend was higher for AM vs. PM (4.3 mits/mm2, se=0.9 vs. 3.2, se=0.4, p=.216). In summary, our 
study suggests that there are differences between patient and tumor characteristics of AM vs. PM. 
Further studies are warranted to evaluate if screening and management of certain populations for 
AM may help improve AM detection and outcomes.    
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Inhibition of histone deacetylase 3 overcomes BRAF-inhibitor resistance
X Wang, A Velez, C St. Claire and AS Paller Dermatology, Northwestern University, Chicago, 
IL
Small molecule inhibition of BRAF (BRAFi) can prolong survival in advanced melanoma patients 
who have the BRAF V600E mutation. However, most patients develop BRAFi resistance (BRAFi Res) 
and relapse within months. Combining MEK inhibition and BRAFi significantly improves overall 
survival from 65% in mono-therapy with BRAFi to 72% in combination-therapy, but median pro-
gression-free survival was just from 7.3 months to 11.4 months, suggesting that more complicated 
mechanisms are involved. We have previously found that: (1) increased expression of histone 
deacetylase 3 (HDAC3) correlates with augmented melanoma metastasis; and (2) disrupting HDAC3 
abrogates melanoma cell growth and survival by down-regulating PI3K/Akt and mTOR/p70S6K, 
two signaling pathways that are frequently activated in BRAFi Res melanomas. We hypothesized 
that HDAC3 inhibition (HADC3i) could improve or overcome BRAFi Res. To evaluate the effect 
of HDAC3 expression on BRAFi Res, HDAC3 was disrupted genetically with an siRNA against 
HDAC3 or biochemically with small molecule inhibitors. Treatment of BRAFi Res cells with HDAC3 
siRNA knocked down HDAC3 by 87%, and small molecule inhibitors (MS-275, Kpt-185, YC-5-164, 
YC-5-165 and YC-5-169) significantly prevented HDAC3 phosphorylation and/or reduced HDAC3 
cellular distribution. Using live cell imaging of cell cycle/division and apoptosis, qRT-PCR and 
immunoblotting, we found that treating BRAFi Res cells with both BRAFi and HDAC3i reduced 
cell mitosis (2.5+0.6% vs 11.6+1.5%, p<0.01) and increased apoptosis (56.3+ 3.5% vs. 4.2+0.5%, 
p<0.001) in comparison to cells treated with BRAFi only. Disrupting HDAC3 in BRAFi Res cells 
also inhibited p-PI3K by 6.7-fold, p-Akt473 by 4.3-fold, p-Akt308 by 5.8-fold, p-mTOR by 2.6-
fold and p-p70S6K by 6.8-fold (all p<0.05) when compared to BRAFi Res cells without HDAC3i 
treatment. These results suggest that suppression of PI3K/AKT and mTOR/p70S6K signaling with 
HDAC3 inhibition reverses BRAFi Res and further supports the use of HDAC3 and BRAF inhibitor 
combination therapy for melanomas refractory to BRAF inhibition alone.    
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XPA-induced autophagy promotes cisplatin resistance in melanoma cells
R Ge, L Liu, T Gao and C Li Department of Dermatology, Xijing Hospital, Fourth Military 
Medical University, Xi’an, China
Xeroderma pigmentosum complementation group A (XPA), a key factor in nucleotide excision repair 
(NER), has been shown to play an important role in the resistance to chemotherapy. However, the 
role of XPA in the resistance to cisplatin for the treatment of melanoma is largely unknown. In the 
current study, we show that the levels of XPA were highly correlated with the sensitivity to cisplatin 
in different melanoma cell lines, and the treatment of cisplatin could increase the level of both XPA 
and autophagy in malignant melanocytes. Furthermore, the knockdown of XPA protein level by 
small interfering RNA inhibited the autophagy induced by cisplatin and increased the sensitivity of 
melanoma cells to cisplatin. Moreover, we found that the autophagy induced by cisplatin contrib-
uted to cisplatin resistance of melanoma cells. At last, western blot analysis showed that the lesional 
expression of XPA in advanced melanoma was much higher than that in primary melanoma. Taken 
together, these results demonstrate the role of XPA in promoting autophagy and in turn facilitating 
the cisplatin resistance in melanoma. In addition, the combination of cisplatin and autophagy 
inhibitor could be a potential therapeutic intervention in the treatment of advanced melanoma.   
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MSX1-induced neural crest-like reprograming promotes melanoma progression
M Fukunaga-Kalabis,1 M Heppt1, 2, J Wang,1 D Hristova,1 Z Wei,3 M Irmler,4 C Berking,2 
R Besch,4 J Beckers,4 FJ Rauscher,1 DE Fisher5 and M Herlyn1 1 The Wistar Institute, 
Philadelphia, PA, 2 Department of Dermatology and Allergology, Ludwig-Maximilian 
University, Munich, Germany, 3 Department of Computer Science, New Jersey Institute of 
Technology, Newark, NJ, 4 Institute of Experimental Genetics, Helmholtz Zentrum München 
GmbH, Neuherberg, Germany and 5 Massachusetts General Hospital, Boston, MA
Malignant melanomas develop from melanocytes. Highly aggressive, therapy-refractory melanomas 
often lack pigment-related markers, but instead express neural crest-specific genes. The various 
implications of neural crest genes in cancer prompted us to investigate whether the neural crest-
like phenotype contributes to melanoma progression. The homeodomain transcription factor Msh 
homeobox 1 (MSX1) is known to be essential for neural crest specification. Here, we examined the 
role of MSX1 in melanocytes and in melanoma. MSX1 is highly expressed in multipotent neural 
crest stem cell-like cells (NCSC-like cells) isolated from human dermis and in a panel of melanoma 
cell lines and patients’ tissues. MSX1-transduced melanocytes lost pigmentation and gained the 
expression of neural crest markers, suggesting that these cells represent a dedifferentiated phe-
notype. Furthermore, these melanocytes were able to survive under human embryonic stem cell 
(hESC) culture conditions and were susceptible to differentiation into neuronal and mesenchymal 
lineages. Mechanistically, we identified M-MITF as a direct target of MSX1. Expression of MSX1 was 
correlated with disease progression in melanoma. Overexpression of MSX1 promoted cell motility 
in both melanocytes and melanoma cells and induced substantial changes in cell morphology, 
while silencing MSX1 by shRNA significantly inhibited melanoma migration in vitro and metastasis 
formation in vivo. Taken together, these results suggest that the neural crest-like reprogramming 
process conferred by MSX1 contributes to the metastatic spread of melanoma.    
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Measurement of skin pigmentation using a chromameter in a 3-dimensional epidermal model 
containing functional melanocytes
MA Bachelor, B Breyfogle and M Klausner MatTek Corporation, Ashland, MA
Considerable interest exists in evaluating effects on skin pigmentation resulting from treatment 
with raw materials, skin care formulations, or as a side effect induced by medication. A convenient 
way to screen such effects utilizes the MelanoDerm tissue model, a highly differentiated, three-di-
mensional tissue culture model of human epidermis containing normal human melanocytes and 
keratinocytes. Use of this in vitro model can provide valuable in vitro data as an early screening 
tool prior to the commencement of costly clinical trials. In this study, pigmentation was evaluated 
over the course of 2-3 weeks using a tristimulus chromometer to measure brightness (L*), yellow-
ness (b*) and redness (a*) in MelanoDerm tissue produced with normal human melanocytes from 
Black, Asian, or Caucasian donors. In parallel to measurements taken with the chromameter, total 
melanin content of tissues was also quantified. Over time, cultures became increasingly pigmented 
with retention of normal epithelial morphology with the expected pigmentation level of the donor 
tissue, i.e. Black>Asian>Caucasian when cultured in media containing alpha-MSH and beta-FGF. 
Several over-the-counter skin lightening products were also evaluated in cultures containing nor-
mal human melanocytes from Black donors. Over the 2-3 week treatment period, control cultures 
became increasingly pigmented while tissues treated topically with cosmetic skin lightening agents 
containing tyosinase inhibitors such as kojic acid and magnesium ascorbyl phosphate remained 
distinctly lighter when compared to control cultures. After 14 days in culture, total melanin content 
was found to inversely correlate with surface reflectance (L*). The results described herein suggest 
that this model is useful for evaluating effects on melanogenesis, skin lightening, and other pigmen-
tation phenomena of skin in vitro. In particular, this study highlights two distinct endpoints, total 
melanin content and skin color measurement that can be used to evaluate skin pigmentation in vitro.   
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Strategic use of BCL-2 inhibitors to target melanoma cells and melanoma initiating cells
N Mukherjee,1 C Shiau,2 Y Lu,1 AR Almeida,1 JV Schwan,1 Y Luo,1 M Fujita,1 S Robinson,3 
W Robinson,3 D Norris1 and YG Shellman1 1 Dermatology, University of Colorado, AMC, 
Aurora, CO, 2 Institute of Biopharmaceutical Sciences, Taipei, Taiwan and 3 Division of 
Medical Oncology, University of Colorado, AMC, Aurora, CO
Currently approved drugs for melanoma have produced promising results, but many patients even-
tually relapse and individuals without the BRAFV600E mutation still have limited options. Dysreg-
ulation of BCL-2 family contributes to melanoma’s resistance to treatments; eliminating melanoma 
initiating cells (MICs) should be part of drug development to prevent relapse. Therefore this study 
tested the efficacy in killing melanoma cells and MICs of SC-2001 (an obatoclax derivative BCL-2 
family inhibitor), either alone or in combination with ABT-737 (a small molecule BCL-2/BCL-XL/
BCL-W inhibitor). Interestingly, we found SC-2001 alone effectively de-bulked melanoma cells, 
but only the combination effectively eradicated the MICs. We used in vitro assays and mouse 
xenograft models: cell viability/apoptosis assays, immunoblot, shRNA techniques, as well as cancer 
stem cell analyses by Aldefluor and sphere formation assays. SC-2001 by itself induced apoptosis 
in melanoma cell lines and inhibited tumor growth in vivo (p<0.01). However, even at high doses 
(10μM), SC-2001 alone did not effectively eliminate MICs. In contrast, the combination of low dose 
SC-2001 (2.5μM) with ABT-737(3.3μM) decreased ALDH+ cells, disrupted primary spheres forma-
tion, and more effectively inhibited the self-renewability of MICs (p < 0.05). Results were similar in 
multiple melanoma cells, regardless of the mutation status of BRAF or NRAS. In vivo experiments 
with low cell number are in progress to further examine the effects of the combination on MICs. 
Mechanistic studies identified the upregulation of the pro-apoptotic protein NOXA as one of the 
significant contributors. Thus, this study suggests that the sequential use of a single agent following 
by the combination of BCL-2 inhibitors is a promising treatment strategy for melanoma, regardless 
of mutation status of BRAF or NRAS.    
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The adverse correlation of primary cilia in melanoma is likely independent of proliferation 
and cell cycle progression 
ER Snedecor1, 2, C Sung1, 3, A Moncayo1, 4, B Rothstein1, 5, D Mockler,1 M Tonnesen6, 
7, E Jones,6 M Fujita,8 RA Clark6, 4, KR Shroyer1 and J Chen1, 6 1 Pathology, Stony Brook 
University, Stony Brook, NY, 2 Program in Genetics, Stony Brook University, Stony 
Brook, NY, 3 School of Medicine, Stony Brook University, Stony Brook, NY, 4 Biomedical 
Engineering, Stony Brook University, Stony Brook, NY, 5 School of Medicine, Tufts University, 
Medford, MA, 6 Dermatology, Stony Brook University, Stony Brook, NY, 7 Dermatology, 
Northport VA Medical Center, Northport, NY and 8 Dermatology, University of Colorado 
Denver, Denver, CO
The primary cilium is a cellular organelle that exists in melanocytes and melanoma cells. Recently, 
frequent depletion of primary cilium was observed in melanoma, suggesting that primary cilium may 
be used as a biomarker for melanoma. However, the statistical power of using primary cilium as a 
biomarker remained to be determined. It also remained unclear whether the loss of cilia in mela-
noma was due to increased proliferation or cell cycle progression. Here, we evaluated primary cilia 
in 87 cases of melanocytic nevi and melanomas and found highly significant reduction in ciliated 
cells in all types of melanoma compared to nevi. This trend was similarly observed when only the 
non-proliferating cells were examined. Furthermore, when paired melanoma cell lines (cell lines 
derived from primary tumors and metastatic tumors of the same patients) were analyzed, we found 
that metastatic melanoma cells contained significantly fewer ciliated cells, while cell cycle profiles 
of all cell lines were comparable. Thus, data obtained from this study suggest that the loss of cilia 
is adversely correlated with melanoma, which is unlikely caused by increased proliferation or cell 
cycle progression in melanoma. Further investigation on the molecular mechanism underlying loss 
of primary cilia in melanoma may help to understand malignant transformation and invasion of mel-
anoma, and identify novel therapeutic avenues to reduce melanoma-related morbidity and mortality.   
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Switching the enemy: The anti-leprotic clofazimine displays anti-melanoma activity through 
induction of genotoxic stress
SL Park, AL Davis, H Li, S Qiao, JD Williams and GT Wondrak Pharmacology and Toxicology, 
College of Pharmacy and Arizona Cancer Center, University of Arizona, Tucson, AZ
Even though the development of molecularly targeted therapeutics has recently revolutionized mel-
anoma chemotherapy, an urgent need persists for the identification and development of improved 
molecular agents. Guided by gene expression array analysis and a phenotypic screen interrogat-
ing the anti-proliferative activity of a collection of clinical antimicrobials, we have identified the 
redox-directed phenazinium-quinoneimine pharmacophore clofazimine (CFZ), an anti-leprotic 
used clinically worldwide, as an experimental melanoma chemotherapeutic. Unbiased expression 
array analysis indicated that CFZ exposure (10 μM, 24 h) causes upregulation of genotoxic stress 
response and DNA damage repair genes (RAD50, ERCC1, GADD45A, TP53, ERCC3, XRCC1, 
DDB1) in A375 malignant melanoma cells. Immunoblot analysis confirmed pronounced upregu-
lation of RAD50, a component of the MRN DNA damage repair complex. CFZ-induced genotoxic 
stress was confirmed by comet analysis and immunoblot detection of activational phosphorylation 
of Chk1 (Ser345) and p53 (Ser15). CFZ displayed potent anti-proliferative activity in a panel of 
human malignant melanoma cell lines (A375, G361, LOX-IMVI) causing S-phase cell cycle arrest 
with hypophosphorylation of Rb (Ser780, Ser807/811), upregulation of p21, and downregulation 
of cyclin D1 protein levels. Consistent with the established mechanistic involvement of oxidative 
stress in the anti-leprotic activity of CFZ, upregulation of genes encoding components of redox stress 
response pathways (EGR1, PRDX2, HMOX1, GSR) was also observed in A375 cells. Combined 
with clinical data that document the longterm safety and systemic availability of CFZ achieving 
high and sustained tissue concentrations in the context of chemotherapy targeting Mycobacterium 
leprae, these data warrant further investigations that test feasibility of repurposing clofazimine as 
an anti-proliferative melanoma chemotherapeutic.    
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IL-23 prevents melanoma development through multiple mechanisms
TH Nasti, M Athar, L Timares and CA Elmets Dermatology, University of Alabama at 
Birmingham, School of Medicine, Birmingham, AL
Anti-cytokine therapies (e.g. anti-IL-12/IL-23) are widely used to treat autoimmune diseases. Their 
long-term effects is an important issue that has not been thoroughly investigated. Because IL-12 and 
IL-23 play a critical role in tumor development, their role in the formation of pigmented lesions and 
their progression to melanoma was evaluated in a murine model. Wild-type (WT), IL-12p35KO, 
IL-23p19KO, and IL-12/23p40KO mice were treated with dimethylbenz(a)anthracene (DMBA) fol-
lowed by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) in order to produce pigmented dysplastic 
nevi that evolve into melanoma, with some progression to metastatic melanoma. IL-23p19KO mice 
developed 2-fold more lesions with increased radial growth (p<0.001) compared to WT mice. 
In contrast, there was not a statistically significant difference in the size or number of lesions in 
IL-12p35KO mice compared to WT mice. After 25 weeks, draining lymph nodes (dLNs) were exam-
ined histologically for melanocytic foci. An increase in the number and size of melanocytic cell foci 
was observed in the dLNs from IL-23p19KO compared to IL-12p35KO and WT controls (p<0.01). 
Continuous melanocytic cell lines were easily established from nevi and dLN of the IL-23p19KO 
mice. The lines exhibited attachment independent growth and tumor growth in nude mice. Pri-
mary melanocyte cultures from IL-23p19KO mice exhibited delayed DNA repair in response to 
DMBA, while WT melanocytes exhibited enhanced DNA repair when rIL-23, but not rIL-12, was 
added to cultures. Immunological alterations were also identified in KO mice. An increase in the 
number and function of regulatory T-cells was observed in IL23p19KO versus IL12p35KO and 
WT mice. IL-23p19KO mice were found to secrete very high levels of IFN-γ (shown to promote 
the development of melanomas in murine models). WT mice treated with neutralizing IFN-γ mAb 
developed significantly fewer lesions (p<0.05) than mice treated with control Abs. These results 
describe novel roles for IL-23-mediated inhibition of melanoma initiation and progression, through 
direct and indirect mechanisms.    
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Deregulation of chemotactic signals, leukocyte recruitment, and immunity in segmental 
vitiligo
M El-Domyati,1 W Hosam El-Din,1 A Fawzy Rezk1, 2, J Uitto,2 O Igoucheva2 and V Alexeev2 1 
Dermatology Department, Minia University, Minia, Egypt and 2 Dermatology and Cutaneous 
Biology, Thomas Jefferson University, Philadelphia, PA
Generalized non-segmental vitiligo (NSV) was recently re-evaluated as an autoimmune disorder. 
There also have been few reports suggesting a contribution of the immune system to the progression 
of segmental vitiligo (SV). With the knowledge that chemokines, small protein molecules that direct 
trafficking of leukocytes, play an important role in the activation and maintenance of the immune 
response, we assessed chemotactic molecules in the skin and blood of patients affected by segmental 
vitiligo at different stages of disease progression. Only minor changes including slightly elevated 
levels of CCL27 and CCL11 were detected in the blood of SV patients. However, significantly higher 
levels of the intra-cutaneous CCL27, CCL11, CCL24, CCL22, CXCL12 and CCL5 were detected in 
the vitiliginous skin. Elevated chemokines within perilesional and lesional SV skin were associated 
with infiltration of the skin with leukocytes, which were more prominent in samples of SV with the 
recent onset (less than 4 months). Remarkably, higher expression of several de-regulated chemok-
ines was restricted to melanocytes in the perilesional skin. Further characterization of lesional and 
perilesional skin showed prominent infiltration with CXCL12+ dendritic cells, CCR4+ T cells, and 
eosinophils. All infiltrating cells were clustered at the dermal-epidermal junction of the perilesional 
skin. Some of the infiltrating cells were also detected within the epidermis. Contrary to perilesional 
skin, infiltrates were detected mostly in the dermis in SV lesions. This pattern of de-regulated che-
motactic molecules in the SV-affected skin was similar to that identified in the NSV-affected skin of 
recent onset (less than 2 months). Collectively, these studies confirmed the contribution of adaptive 
immunity to the onset and progression of SV, and potential contribution of the melanocytes to the 
recruitment of leucocytes and “self-elimination”    
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Evaluation of a topical formulation containing myristyl nicotinate for modulating melanin 
production in comparison to a formulation containing hydroquinone 
S Rao Product Development, StriVectin Operating Company, New York, NY
The objective of this study was to determine the efficacy of a topical formulation containing myristyl 
nicotinate when combined with multiple cosmetic ingredients; to induce changes in pigmentation 
in comparison with a formulation containing hydroquinone. A methodology was designed to assess 
the potential of a myristyl nicotinate containing cosmetic formulation (test material) to induce 
changes in tissue pigmentation using an in-vitro tissue model of the human epidermis prepared from 
cultured human keratinocytes and melanocytes. After obtaining favorable results from the in-vitro 
study a double blind clinical study on thirty seven panelists aged 32-65 was designed to evaluate 
the efficacy of the test material for overall skin brightening and skin tone modulation. The 12 week 
clinical study was designed evaluate the test material and a commercially available formulation 
containing Hydroquinone (2%). Qualified dermatological evaluation, image analysis and statistical 
analysis (Z-test) on consumer perception questions were assessed at week 4, 8 and 12 respectively. 
The results of the in-vitro study indicate that the test material had a statistically significant reduction 
in the melanin content in comparison to the formulation containing hydroquinone. Additionally, 
the test material had a statistically significant decrease in melanin content compared to the lotion 
vehicle. While the hydroquinone treated tissues also saw a significant reduction in melanin content, 
the decrease observed with the test material was statistically better than the tissues treated with 
hydroquinone. Clinical results (in-vivo) indicate that the test material showed statistically significant 
improvement in multiple parameters for skin brightening. In conclusion, the test material containing 
myristyl nicotinate was able to favorable induce a change in the over-expression of melanin with 
the test material performing better than hydroquinone in-vitro and comparable to hydroquinone 
in clinical studies.    
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4’-Bromo-resveratrol, a new small molecule inhibitor of SIRT3, imparts anti-proliferative 
effects and causes metabolic reprograming of human melanoma cells
J George1, 2, M Nihal1, 2, CK Singh1 and N Ahmad1, 2 1 Dermatology, University of Wisconsin, 
Madison, WI and 2 William S. Middleton VA Medical Center, Madison, WI
Sirtuin-3 (SIRT3), an important member of sirtuin family, is localized to mitochondria where it 
deacetylases mitochondrial proteins and regulates a variety of cellular functions. Earlier, we have 
demonstrated that SIRT3 is overexpressed in human melanoma cells and tissues and its genetic 
knockdown resulted in a significant antiproliferative response in human melanoma cells (JID 134, 
S121-S131, 2014), suggesting that small molecule inhibitor(s) may be useful for melanoma manage-
ment. In this study, we determined the effect of a small molecule SIRT3 inhibitor, 4’-bromo-resver-
atrol (4BR), in human melanoma cells (G361, SK-MEL-28 and SK-MEL-2). We found that treatment 
of melanoma cells with 4BR (12.5-200 X 10-3 mM; for 24-72 h) resulted in a significant dose- and 
time- dependent decrease in cell proliferation. Further, 4BR treatment also resulted in a marked 
decrease in the growth/viability, clonogenic survival and migration ability of melanoma cells. Fur-
thermore, 4BR treatment was found to cause a marked downregulation of proliferating cell nuclear 
antigen (PCNA) protein and SIRT3 mRNA and protein. In addition, 4BR treatment to melanoma cells 
caused a 1) an induction of apoptosis (PARP cleavage), decrease in pro-caspase-3, pro-caspase-8, 
and 2) G0/G1 phase cell cycle arrest. These effects were accompanied by an increase in the protein 
levels of p21Waf1 and decrease in cyclin D1 and cdk2. Interestingly, our data also demonstrated that 
4BR resulted in a metabolic reprograming in human melanoma cells as evident from decrease in the 
levels of 1) lactate production, 2) glucose uptake, 3) NAD+/NADH ratio, 4) lactate dehydrogenase 
A (LDHA) and glucose transporter 1 (Glut1) proteins. Taken together, our data suggested that SIRT3 
small molecule inhibition via 4BR (or other pharmacological means) could be developed as a novel 
therapeutic strategy against melanoma. Further research is ongoing in our laboratory to ascertain 
the mechanism and in vivo significance of our finding.    
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105F is a novel immunoadaptive treatment candidate for melanoma that induces apoptosis 
and the secretion of pro-inflammatory IL-6
E Pinney,1 C Posch,2 A Betancourt,3 M Montes-Camacho1 and G Naughton1 1 Histogen, Inc., 
San Diego, CA, 2 Dermatology, UCSF, San Francisco, CA and 3 WibiWorks Therapeutics, 
San Diego, CA
We have previously shown that a low molecular weight subfraction (105F) of human cell condi-
tioned media (CCM) from hypoxia-induced multipotent cells grown in a perfusion bioreactor system 
inhibits tumor cell growth in vitro and in two animal models. We have further studied the mechanism 
of action as it related to melanoma. Uveal and nRAS melanoma cancer cell growth was inhibited 
by greater than 90% in in-vitro proliferation assays. Immunostaining of Annexin V and immunoblot 
analysis suggest that the mechanism of action of the 105F is through the induction of apoptosis by 
the upregulation of Caspase 3 and 9. In the TUMCAM assay, melanoma load was reduced by up 
to 80% with 105F treatment compared to controls (p < 0.05). To further elucidate the mechanism 
involved custom kinome array assays were performed on two chemotherapy resistant melanoma 
cell lines, DO4 and C918. The results indicated that the induction of apoptosis is downstream from 
Toll-like receptor (TLR) signaling pathways. Results also implicated adaptive immune responses 
including the secretion of pro-inflammatory cytokines. As such, ELISA analyses showed the release 
of IL-6 from the DO4 melanoma cells after treatment with 105F. Such an immune “flare” could be 
critically important in recruiting immune cells to the tumor for cytotoxic attack. To further study the 
effects of 105F on tumors and the immune system, colony forming units (CFU) assays were done 
with co-cultures of mesenchymal stem cells (MSCs) primed to be pro-inflammatory (MSC1) and 
DO4 or B16 melanoma. Both human and mouse cancer colonies were diminished in the MSC1 
alone treatment, colonies were smaller and tighter after 105F alone treatment, and colonies were 
synergistically diminished after the combined treatment. These results support a role for 105F in a 
novel immunoadaptive treatment for melanoma.    
      
      
